ESR1 and breast carcinoma: Overall survival (OS) of patients with breast cancers showed that a low RNF5 expression level was correlated with better survival in patients with estrogen receptor (ER)-positive breast cancers (Fig. 6B) but with poorer survival in patients with ER-negative breast cancers (Fig. S3A), indicating that estrogen receptor signaling might be required for the tumor-promoting function of RNF5 in breast cancers.